Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, ...

The nasal spray had to go through many rounds of clinical testing, with some shown to improve depression, while others showed no improvement over a placebo. In 2019, the FDA approved Spravato for ...

The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" under medical supervision and has a prescription from "an actual, real doctor." ...

Neurelis, Inc., today announced details of three poster presentations at the American Academy of Neurology (AAN) Annual ...

However, while oxytocin was seen to increase in the breast milk of women without postnatal depression after using a nasal spray containing the hormone, this effect was reduced in mothers ...